Human Erythrocyte-Based Hemolysis Assay: A Non-Animal Alternative for Quantifying Complement System Pathway Activity

This study details the development and validation of Chemically and Enzymatically Modified human Erythrocytes (ChEME) as a robust replacement for animal-derived cells in hemolysis assays. Traditional methods for evaluating human complement activity rely on sensitized sheep or rabbit erythrocytes, which present ethical concerns and inter-species variability.Key Technical Highlights:ChEME Methodology: Sequential treatment of human erythrocytes with 2,4,6-trinitrobenzene sulfonate (TNBS) and pancreatin to enhance susceptibility to complement-mediated lysis.Pathway Specificity: Evaluation of the Classical Pathway (CP) and Alternative Pathway (AP) through selective chelation and restoration of calcium ions.Assay Optimization: Demonstrated significantly greater hemolysis with combined chemical/enzymatic treatment compared to single-agent protocols.Clinical Utility: Validated for screening complement deficiencies, monitoring inflammatory diseases, and testing therapeutic complement inhibitors.This research provides a sustainable, high-precision framework for functional complement assays in clinical settings, eliminating the need for animal-derived blood products while maintaining diagnostic accuracy.